Clinical trial
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or…
NCT00005081 · Duke University, Other · Completed
Key facts
| NCT number | NCT00005081 |
|---|---|
| Title | Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma |
| Official title | Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | O6-benzylguanine, carmustine |
| Start date | Aug 1, 2000 |
| Primary completion | Apr 1, 2001 |
| Completion | Apr 1, 2001 |
| First posted | May 3, 2004 |
| Last update posted | Aug 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: